A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Ann Oncol
; 23(10): 2687-2695, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-22767588
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfoma Folicular
/
Neoplasia Residual
/
Transplante de Células-Tronco Hematopoéticas
/
Anticorpos Monoclonais Murinos
/
Antineoplásicos
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article